Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Up - Here's Why

Key Points

• Chugai Pharmaceutical shares gapped up pre-market, opening at $23.65 after a previous close of $22.11. The last trade was at $22.78 with a volume of 30,985 shares.
• The company reported a strong quarterly performance, with $2.01 billion in revenue and earnings per share (EPS) of $0.20, while analysts forecast an annual EPS of 0.74.
• Chugai Pharmaceutical has a market capitalization of $75.30 billion and a return on equity of 20.80%, indicating robust financial health.

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $22.11, but opened at $23.65. Chugai Pharmaceutical shares last traded at $22.78, with a volume of 30,985 shares.

Chugai Pharmaceutical Stock Up 3.5%

The company has a market cap of $75.30 billion, a price-to-earnings ratio of 28.96 and a beta of 0.64. The company has a fifty day simple moving average of $22.61 and a two-hundred day simple moving average of $24.37.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last issued its quarterly earnings data on Thursday, July 24th. The company reported $0.20 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a return on equity of 20.80% and a net margin of 33.08%.The business had revenue of $2.01 billion for the quarter. On average, research analysts predict that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 EPS for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.